肿瘤细胞治疗研究
FRONTIER PAPERS
CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas.
嵌合抗原受体（CAR）T 细胞疗法治疗实体瘤的成功有限，部分原因是肿瘤异质性和抗原逃逸。
Advancing liver cancer treatment with dual-targeting CAR-T therapy.
靶向磷脂酰肌醇蛋白聚糖-3（GPC3）的嵌合抗原受体（CAR）-T 细胞疗法在肝细胞癌（HCC）治疗中已显示出前景。
Glypican 3-targeted chimeric antigen receptor T cells secreting TROP2-directed bispecific T cell engagers exhibit potent efficacy against lung squamou
本研究表明，GPC3 CAR-T。
A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTE(FAP5/CD3), CAR-T cells, and immunotoxins in hep
这种高阶联合代表了一种针对肝细胞癌的新型多波次免疫治疗策略。
Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma.
使用抗 FAP-GPC3 双特异性 CAR-T 细胞是一种有前景的治疗方法，可减少由肿瘤抗原异质性引起的肿瘤复发。
Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC.
在肿瘤微环境（TME）的持续刺激下，程序性死亡 1（PD-1）表达升高，并与 PD 配体 1（PD-L1）相互作用，导致 CAR-T 细胞功能障碍。
GPC-3 in hepatocellular carcinoma; A novel biomarker and molecular target.
肝细胞癌（HCC）因诊断晚和复发率高而成为全球健康问题。
GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assa
我们的研究显示，GPC3-BiTE CAR-T 细胞比单靶点 CAR-T 细胞表现出更强的抗肿瘤活性，且能够克服抗原异质性引起的肿瘤逃逸，提示这可能是一种有前景的肝细胞癌治疗策略。
Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.
我们的研究表明，通过非病毒 mcDNA 载体制备双特异性 CAR-T 细胞具有更高的效率和安全性。CoG133-CAR-T 细胞通过双抗原识别和内部激活增强了肿瘤抑制能力。这为 HCC 乃至实体瘤的 CAR-T 治疗提供了一种创新策略。
A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding.
LAG3 是表达于活化 T 细胞和 NK 细胞上的抑制性免疫检查点。
共 10 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
